The mortality rates were 15.5% for the ibrutinib group and 16.3% for the bendamustine group. Significant cardiovascular risks are associated with ibrutinib treatment in patients with chronic ...

Rosalind Kalb is lead senior programs consultant for Can-Do MS, a Colorado-based nonprofit health and wellness organization. Larry Luxner, senior correspondent for Rare Disease Advisor, interviews ...

This particular combination of mutations and comorbidities led to an aggressive disease course, which was refractory to standard treatments. The report, published in Case Reports in Hematology, ...

For T2 signal intensity (SI), there was a significant and strong correlation between SI and the number of days since the last IUT, with SI initially reduced and recovering over time. A recent study ...

Sandy Siegel, founder and president of the Siegel Rare Neuroimmune Association (Photo by Larry Luxner) Anthropologist Sandy Siegel launched the group after his late wife was diagnosed with transverse ...

Physical exercise rehabilitation programs can optimize outcomes in patients with PAH, especially when performed under clinical supervision. Continuous patient-facing medical education empowers ...

Only patients with PBC had an observable correlation between SOS and disease progression status. Systemic oxidative stress (S0S) caused by vitamin D deficiency correlates with decreased quality of ...

Studies have identified various differences in HDFN management and monitoring practices across the United States that could lead to poorer outcomes. For modern medicine to function at an optimized ...

Anaphylaxis can sometimes present as the initial complaint in patients who are later diagnosed with systemic mastocytosis. A severe anaphylactic reaction can be life-threatening, and once ...

As of November 2024, approximately 156 clinical trials for Duchenne muscular dystrophy (DMD) are ongoing or pending: 16 trials not yet recruiting, 65 currently recruiting, 28 trials that are active ...

After an open-label phase 2 trial found proof-of-concept efficacy for nipocalimab in the treatment of pregnant women at high risk of hemolytic disease of the fetus and newborn (HDFN), researchers are ...

Living with Pompe disease is a constant battle requiring physical resilience and emotional strength. And it requires the ability to adapt to a life that progressively becomes more challenging. Yet, ...